The Belgian diagnostic startup Antelope DX has concluded its B financing round of 9 million euros. The round was subscribed in a 50/50 ratio by an investment consortium led by Whitefund, and the existing A-round investors. This fundraising will further the Ghent-based company in its goal to bring a broad menu for the individual to test relevant parameters at home: from acute infection detection to disease monitoring using various sample types.
Antelope is going to use the fresh capital to initiate clinical development of its urine-based self-test for the sexually transmitted diseases Chlamydia trachomatis and Neisseria gonorrhea towards an in-vitro diagnostic product. Furthermore, it’s working on a respiratory Influenza A/B and Sars-CoV-2 test with a single swab, enabling worried individuals to test in their home setting. Developments also include quantitative measurements of protein biomarkers in a finger-prick blood sample.
Antelope’s solution sets itself apart by offering three features that are typically very difficult to combine: clinical lab performance with the ease-of-use of a pregnancy test at a consumer price tag. The platform is based on innovative lab-on-chip technology that is the result of ten years of research at the Photonics Research Group of Ghent University. From mid-2018 to mid-2019, the technology was further incubated in Mycartis, an immuno-diagnostic solution provider that itself has its roots in Biocartis (link in Dutch). Last year, after raising 5.1 million euros, Antelope was established as a spinoff from UGhent and Mycartis, located in the Bioscape incubator in Ghent-Zwijnaarde.